Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio (NASDAQ: GOSS) has announced the approval of inducement grants under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock options for three non-executive employees to purchase up to 510,000 shares of common stock, effective February 5, 2025.
The options have an exercise price of $1.15 per share, matching the closing price of Gossamer's stock on February 5, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment. The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Gossamer Bio (NASDAQ: GOSS) ha annunciato l'approvazione di incentivi ai sensi del suo Piano di Assegnazione di Incentivi per l'Occupazione 2023. Il Comitato per la Compensazione ha approvato opzioni su azioni non qualificate per tre dipendenti non esecutivi per acquistare fino a 510.000 azioni di azioni ordinarie, con efficacia dal 5 febbraio 2025.
Le opzioni hanno un prezzo di esercizio di $1.15 per azione, corrispondente al prezzo di chiusura delle azioni di Gossamer del 5 febbraio 2025. Queste opzioni decennali matureranno in quattro anni, con il 25% che matura dopo un anno e il saldo restante che matura in 36 rate mensili, a condizione di mantenere l'impiego. Gli incentivi sono stati concessi come premi per l'occupazione in conformità con Nasdaq Listing Rule 5635(c)(4).
Gossamer Bio (NASDAQ: GOSS) ha anunciado la aprobación de incentivos salariales bajo su Plan de Asignación de Incentivos para la Empleo 2023. El Comité de Compensación aprobó opciones sobre acciones no calificadas para tres empleados no ejecutivos para comprar hasta 510,000 acciones de acciones ordinarias, que serán efectivas el 5 de febrero de 2025.
Las opciones tienen un precio de ejercicio de $1.15 por acción, igualando el precio de cierre de las acciones de Gossamer el 5 de febrero de 2025. Estas opciones de diez años se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el saldo restante consolidándose en 36 pagos mensuales, sujeto a la continuación del empleo. Las concesiones se hicieron como incentivos laborales de acuerdo con Nasdaq Listing Rule 5635(c)(4).
Gossamer Bio (NASDAQ: GOSS)는 2023년 고용 유도 인센티브 수여 계획에 따른 유인 보상의 승인을 발표했습니다. 보상 위원회는 세 명의 비상임 직원에게 일반 주식 51만 주를 구매할 수 있는 비정규 주식 옵션을 승인했습니다. 이는 2025년 2월 5일부로 효력을 발생합니다.
옵션의 행사 가격은 $1.15 per 주로, 2025년 2월 5일 Gossamer 주식의 종가와 일치합니다. 이 10년 옵션은 4년에 걸쳐 만기가 되어 1년 후에 25%가 발생하고 나머지 잔액은 고용이 지속되는 조건으로 36개월에 걸쳐 분할됩니다. 인센티브는 Nasdaq Listing Rule 5635(c)(4)에 따라 고용 유도를 위해 제공되었습니다.
Gossamer Bio (NASDAQ: GOSS) a annoncé l'approbation des attributions d'incitations dans le cadre de son Plan d'Attribution d'Incentives à l'Emploi 2023. Le Comité de Rémunération a approuvé des options d'achat d'actions non qualifiées pour trois employés non-exécutifs leur permettant d'acheter jusqu'à 510 000 actions ordinaires, en vigueur à compter du 5 février 2025.
Les options ont un prix d'exercice de $1.15 par action, correspondant au prix de clôture des actions de Gossamer le 5 février 2025. Ces options de dix ans seront acquises sur quatre ans, avec 25 % acquises après un an et le solde restant acquis en 36 versements mensuels, sous réserve d'un emploi continu. Les attributions ont été faites en tant qu'incitations à l'emploi conformément à Nasdaq Listing Rule 5635(c)(4).
Gossamer Bio (NASDAQ: GOSS) hat die Genehmigung von Anreizen im Rahmen seines Plans für die Anreizvergabe 2023 bekannt gegeben. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen für drei nicht geschäftsführende Mitarbeiter zum Kauf von bis zu 510.000 Aktien gewöhnlicher Aktien, wirksam ab dem 5. Februar 2025.
Die Optionen haben einen Ausübungspreis von $1.15 pro Aktie, was dem Schlusskurs der Gossamer-Aktien am 5. Februar 2025 entspricht. Diese zehnjährigen Optionen werden über vier Jahre fällig, wobei 25% nach einem Jahr fällig werden und der verbleibende Betrag in 36 monatlichen Raten, abhängig von der fortgesetzten Beschäftigung, fällig wird. Die Gewährungen erfolgten als Beschäftigungsanreize gemäß Nasdaq Listing Rule 5635(c)(4).
- Stock option grants help attract and retain talent without immediate cash expenditure
- Four-year vesting schedule promotes long-term employee retention
- Potential future dilution of existing shareholders through 510,000 new stock options
The options have an exercise price of
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207717407/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
FAQ
How many shares are included in Gossamer Bio's (GOSS) February 2025 inducement grant?
What is the exercise price for GOSS's February 2025 inducement stock options?
What is the vesting schedule for Gossamer Bio's (GOSS) February 2025 inducement options?
How many employees received stock options in GOSS's February 2025 inducement grant?
